AIM ImmunoTech Inc. (AMEX:AIM) is a biotechnology company focused on the research and development of immune-based therapies. The company aims to develop treatments for various diseases, including cancer and viral infections. In the competitive landscape, AIM's peers include companies like Aytu BioPharma, Inc., iBio, Inc., Co-Diagnostics, Inc., Cocrystal Pharma, Inc., and NanoViricides, Inc., all of which are involved in similar biopharmaceutical endeavors.
AIM's Return on Invested Capital (ROIC) is an impressive 443.97%, which is significantly higher than its Weighted Average Cost of Capital (WACC) of 6.25%. This results in a ROIC to WACC ratio of 71.06, indicating that AIM is generating returns far above its cost of capital. This suggests efficient capital utilization and strong potential for value creation, making AIM a standout in its industry.
In contrast, AIM's peers show negative ROICs, which are below their respective WACCs. For instance, Aytu BioPharma, Inc. has a ROIC of -2.78% and a WACC of 19.62%, resulting in a ROIC to WACC ratio of -0.14. Similarly, iBio, Inc. has a ROIC of -117.47% and a WACC of 4.94%, leading to a ROIC to WACC ratio of -23.78. These figures indicate that these companies are not currently generating returns that exceed their cost of capital.
Co-Diagnostics, Inc. and Cocrystal Pharma, Inc. also exhibit negative ROICs of -89.02% and -181.96%, respectively, with WACCs of 5.73% and 12.56%. Their ROIC to WACC ratios are -15.54 and -14.49, respectively. NanoViricides, Inc. follows a similar pattern with a ROIC of -111.71% and a WACC of 8.36%, resulting in a ROIC to WACC ratio of -13.36. These negative ratios suggest potential concerns for investors regarding capital efficiency.
Overall, AIM ImmunoTech Inc. demonstrates a strong ability to generate returns well above its cost of capital, making it a standout in this peer group. This high ROIC to WACC ratio suggests that AIM is effectively utilizing its capital to create value, positioning it favorably compared to its peers.
